Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

2.

Regulation of TNF-alpha- and IFN-gamma-induced CXCL10 expression: participation of the airway smooth muscle in the pulmonary inflammatory response in chronic obstructive pulmonary disease.

Hardaker EL, Bacon AM, Carlson K, Roshak AK, Foley JJ, Schmidt DB, Buckley PT, Comegys M, Panettieri RA Jr, Sarau HM, Belmonte KE.

FASEB J. 2004 Jan;18(1):191-3. Epub 2003 Nov 3.

PMID:
14597565
3.

The identification and characterization of the marine natural product scytonemin as a novel antiproliferative pharmacophore.

Stevenson CS, Capper EA, Roshak AK, Marquez B, Eichman C, Jackson JR, Mattern M, Gerwick WH, Jacobs RS, Marshall LA.

J Pharmacol Exp Ther. 2002 Nov;303(2):858-66.

PMID:
12388673
4.

Small-molecule inhibitors of NF-kappaB for the treatment of inflammatory joint disease.

Roshak AK, Callahan JF, Blake SM.

Curr Opin Pharmacol. 2002 Jun;2(3):316-21. Review.

PMID:
12020477
5.

Scytonemin--a marine natural product inhibitor of kinases key in hyperproliferative inflammatory diseases.

Stevenson CS, Capper EA, Roshak AK, Marquez B, Grace K, Gerwick WH, Jacobs RS, Marshall LA.

Inflamm Res. 2002 Feb;51(2):112-4. No abstract available.

PMID:
11926312
6.

The human polo-like kinase, PLK, regulates cdc2/cyclin B through phosphorylation and activation of the cdc25C phosphatase.

Roshak AK, Capper EA, Imburgia C, Fornwald J, Scott G, Marshall LA.

Cell Signal. 2000 Jun;12(6):405-11.

PMID:
11202906
7.

Modulation of human monocyte activities by tranilast, SB 252218, a compound demonstrating efficacy in restenosis.

Capper EA, Roshak AK, Bolognese BJ, Podolin PL, Smith T, Dewitt DL, Anderson KM, Marshall LA.

J Pharmacol Exp Ther. 2000 Dec;295(3):1061-9.

PMID:
11082441
8.

Differential effects of SB 242235, a selective p38 mitogen-activated protein kinase inhibitor, on IL-1 treated bovine and human cartilage/chondrocyte cultures.

Badger AM, Roshak AK, Cook MN, Newman-Tarr TM, Swift BA, Carlson K, Connor JR, Lee JC, Gowen M, Lark MW, Kumar S.

Osteoarthritis Cartilage. 2000 Nov;8(6):434-43.

9.

Human calcium-independent phospholipase A2 mediates lymphocyte proliferation.

Roshak AK, Capper EA, Stevenson C, Eichman C, Marshall LA.

J Biol Chem. 2000 Nov 17;275(46):35692-8.

10.

Decreased nuclear factor-kappaB DNA binding activity following permanent focal cerebral ischaemia in the rat.

Irving EA, Hadingham SJ, Roberts J, Gibbons M, Chabot-Fletcher M, Roshak A, Parsons AA.

Neurosci Lett. 2000 Jul 7;288(1):45-8.

PMID:
10869812
11.

An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage.

Jackson JR, Gilmartin A, Imburgia C, Winkler JD, Marshall LA, Roshak A.

Cancer Res. 2000 Feb 1;60(3):566-72.

12.

Respective roles of the 14 kDa and 85 kDa phospholipase A2 enzymes in human monocyte eicosanoid formation.

Marshall LA, Bolognese B, Roshak A.

Adv Exp Med Biol. 1999;469:215-9.

PMID:
10667333
13.

Anti-human RP105 sera induces lymphocyte proliferation.

Roshak AK, Anderson KM, Holmes SD, Jonak Z, Bolognese B, Terrett J, Marshall LA.

J Leukoc Biol. 1999 Jan;65(1):43-9.

PMID:
9886245
14.

Utility of oligonucleotides as tools to study the function and regulation of 85 kDa phospholipase A2.

Marshall LA, Roshak AK.

Antisense Nucleic Acid Drug Dev. 1998 Apr;8(2):153-7. Review. No abstract available.

PMID:
9593056
15.

Cytosolic 85-kDa phospholipase A2-mediated release of arachidonic acid is critical for proliferation of vascular smooth muscle cells.

Anderson KM, Roshak A, Winkler JD, McCord M, Marshall LA.

J Biol Chem. 1997 Nov 28;272(48):30504-11.

16.

Inhibition of NFkappaB-mediated interleukin-1beta-stimulated prostaglandin E2 formation by the marine natural product hymenialdisine.

Roshak A, Jackson JR, Chabot-Fletcher M, Marshall LA.

J Pharmacol Exp Ther. 1997 Nov;283(2):955-61.

PMID:
9353419
17.

Evidence that 85 kDa phospholipase A2 is not linked to CoA-independent transacylase-mediated production of platelet-activating factor in human monocytes.

Winkler JD, Bolognese BJ, Roshak AK, Sung CM, Marshall LA.

Biochim Biophys Acta. 1997 Jun 2;1346(2):173-84.

PMID:
9219900
18.

Depletion of human monocyte 85-kDa phospholipase A2 does not alter leukotriene formation.

Marshall LA, Bolognese B, Winkler JD, Roshak A.

J Biol Chem. 1997 Jan 10;272(2):759-65.

19.

Manipulation of distinct NFkappaB proteins alters interleukin-1beta-induced human rheumatoid synovial fibroblast prostaglandin E2 formation.

Roshak AK, Jackson JR, McGough K, Chabot-Fletcher M, Mochan E, Marshall LA.

J Biol Chem. 1996 Dec 6;271(49):31496-501.

20.
21.

SB 203347, an inhibitor of 14 kDa phospholipase A2, alters human neutrophil arachidonic acid release and metabolism and prolongs survival in murine endotoxin shock.

Marshall LA, Hall RH, Winkler JD, Badger A, Bolognese B, Roshak A, Flamberg PL, Sung CM, Chabot-Fletcher M, Adams JL, et al.

J Pharmacol Exp Ther. 1995 Sep;274(3):1254-62.

PMID:
7562496
22.
23.

Characterization of phospholipase A2 release by elicited-peritoneal macrophage and its relationship to eicosanoid production.

Marshall LA, Bolognese B, Roshak A.

J Lipid Mediat Cell Signal. 1994 Sep;10(3):295-313.

PMID:
7812679
24.

Characterization of phospholipase A2 from human nasal lavage.

Stadel JM, Hoyle K, Naclerio RM, Roshak A, Chilton FH.

Am J Respir Cell Mol Biol. 1994 Jul;11(1):108-13.

PMID:
8018333
25.

Effects of scalaradial, a type II phospholipase A2 inhibitor, on human neutrophil arachidonic acid mobilization and lipid mediator formation.

Marshall LA, Winkler JD, Griswold DE, Bolognese B, Roshak A, Sung CM, Webb EF, Jacobs R.

J Pharmacol Exp Ther. 1994 Feb;268(2):709-17.

PMID:
8113982
26.
27.

Recombinant human secretory phospholipase A2: purification and characterization of the enzyme for active site studies.

Stadel JM, Jones C, Livi GP, Hoyle K, Kurdyla J, Roshak A, McLaughlin MM, Pfarr DA, Comer S, Strickler J, et al.

J Mol Recognit. 1992 Dec;5(4):145-53.

PMID:
1339483

Supplemental Content

Loading ...
Support Center